A messenger ribonucleic acid (mRNA) competence center is being built at the Halle Biotech site of German company Wacker Chemie AG (WACKER).
Exyte GmbH is a global design, engineering company that delivers facilities for high-tech industries and is in charge of the site at WACKER.
The project is making a considerable contribution towards strengthening the Biopharma and Life Sciences segment at Exyte as well as to the company’s ambitious Pathway to Ten growth path. The WACKER group concentrates its biopharmaceuticals activities within Wacker Biotech, a full-service provider for microbial manufacturing of pharmaceutical proteins.
To mark the construction work at the site, a breaking of ground ceremony this week (July 5) was held at the site in the Weinberger Campus technology park.
Active ingredients based on messenger mRNA used in coronavirus vaccines and in medical products for the treatment of cancer amongst others will be manufactured at the new center.
Four new production lines are to be built on 1,600 m2 of a total floor area of 7,400 m2 and part of the capacities will be made available for the German government for its program to prepare for any future pandemics.
The post Exyte Builds mRNA Competence Center for WACKER in Germany appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.